Table 3.

Cox proportional hazards models for 5 year overall mortality in the China Clinical Trials Consortium validation cohort

	Univariate analysis		Multivariate analysis
	Hazard ratio (95% CI)	Wald test p value	Hazard ratio (95% CI)	Likelihood ratio test p value
Risk category*
High risk	3·07 (2·21–4·25)	<0·0001	2·37 (1·63–3·43)	<0·0001
Intermediate risk	1·87 (1·26–2·77)	0·0019	1·60 (1·03–2·49)	0·0354
Age >65 years	1·11 (0·90–1·37)	0·3337	1·19 (0·94–1·49)	0·1493
Sex (female)	0.78 (0·63–0·95)	0·0150	0·93 (0·70–1·23)	0·6057
Never smoker	0·70 (0·56–0·86)	0·0009	0·84 (0·64–1·10)	0·1986
Histology†
Large-cell carcinoma	2·12 (1·09–4·11)	0·0259	1·68 (0·83–3·41)	0·1831
Mixed	1·67 (1·12–2·48)	0·0118	1·07 (0·69–1·64)	0·7714
NSCLC (not otherwise specified)	0·89 (0·44–1·80)	0·7528	0·77 (0·36–1·63)	0·4759
Stage‡	1·44 (1·35–1·53)	<0·0001	1·43 (1·33–1·53)	<0·0001

NSCLC=non-small-cell lung cancer.

^*Compared with low-risk category.

^†Compared with adenocarcinoma.

^‡Modelled as a continuous variable.